Immunotherapy in genitourinary malignancies.

ABSTRACT:

Purpose of review

Active investigation suggests immune checkpoint inhibitor therapy and therapeutic cancer vaccines provide clinical benefit for genitourinary malignancies including prostate cancer, renal cell carcinoma, and bladder cancer. Recent developments in the utility of immune checkpoint inhibitor and vaccine therapy for the management of genitourinary malignancies are highlighted in this review.

Recent findings

Dramatic responses to checkpoint inhibitor therapy have been demonstrated in renal cell carcinoma and bladder cancer with recent Food and Drug Administration approvals in both indications. No benefit to checkpoint inhibitor therapy has yet been shown for the management of prostate cancer. Therapeutic cancer vaccines have also shown benefit in the treatment of

SUBMITTER: Wattenberg MM 

PROVIDER: S-EPMC5129842 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature